CN102626514A - Soft-shelled turtle systemic septicemia spherical virus inactivated vaccine and its preparation method - Google Patents
Soft-shelled turtle systemic septicemia spherical virus inactivated vaccine and its preparation method Download PDFInfo
- Publication number
- CN102626514A CN102626514A CN2012100187235A CN201210018723A CN102626514A CN 102626514 A CN102626514 A CN 102626514A CN 2012100187235 A CN2012100187235 A CN 2012100187235A CN 201210018723 A CN201210018723 A CN 201210018723A CN 102626514 A CN102626514 A CN 102626514A
- Authority
- CN
- China
- Prior art keywords
- trionyx sinensis
- sinensis wiegmann
- inactivated vaccine
- systematicness
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention discloses a soft-shelled turtle systemic septicemia spherical virus inactivated vaccine and its preparation method, and is characterized in that the vaccine contains the inactivated soft-shelled turtle systemic septicemia spherical virus with the collection number being CGMCCNo.5378. The preparation method comprises the following steps of: cutting internal organ of sick soft-shelled turtles into pieces, adding into a TNE buffer, centrifuging, taking a supernatant, centrifuging, taking a white precipitate, suspending in the TNE buffer, centrifuging the precipitate, taking the supernatant, and centrifuging to obtain a white precipitate, namely the purified virus; diluting the purified virus by the use of aseptic normal saline until the final concentration of viral protein reaches 0.5-1mg/ml, and adding 0.5% (final volume) of formalin for inactivation in a thermostat water bath cauldron; and completely emulsifying inactivated virus and a complete Freund's adjuvant according to the volume ratio of 1:1 to obtain the inactivated vaccine. The soft-shelled turtle systemic septicemia spherical virus inactivated vaccine proposed for the first time is safe and effective and has strong immunity, and the preparation method is simple and easy to operate.
Description
Technical field
The present invention relates to technical field of vaccines, especially relate to a kind of Trionyx sinensis Wiegmann systematicness septicemia spherical viruses inactivated vaccine and preparation method thereof.
Background technology
Trionyx sinensis Wiegmann, the formal name used at school Trionyx sinensis (Wiegmann) always is medicated diet and excellent tonic product.The eighties in 20th century, the rise of greenhouse cultivation significantly improves the output of regarding as rare and precious Trionyx sinensis Wiegmann originally, and what rise is the popular wantonly of disease thereupon.The anti-Zhiduo County of tradition uses antibiotic and chemical drugs to carry out, and for viral disease, not only does not play therapeutic effect, on the contrary Trionyx sinensis Wiegmann is caused murder by poisoning, contaminated environment, and cause drug residue, hit the consumption confidence of consumer.Since 2007; In Zhejiang area; Especially break out a kind of systemic septicemia with Hangzhou, Trionyx sinensis Wiegmann ecologic breeding field, area, Ningbo, cardinal symptom is systemic hemorrhagic deteriorated blood, and research worker is through Epidemiological study, tissue slice and researchs such as ultrathin section observation and artificial challenge's test; Confirm that a kind of novel globular virus is its constitutional virulence factor, this novel globular virus is Trionyx sinensis Wiegmann systematicness septicemia spherical viruses.Trionyx sinensis Wiegmann systematicness septicemia spherical viruses formula isolating a kind of new virus from the morbidity Trionyx sinensis Wiegmann.This virus can cause hemorrhage, the deteriorated blood of Trionyx sinensis Wiegmann systematicness, and the oncoming force is violent, and cumulative mortality can reach 90-100% in 7-10 days.
Vaccine is meant for the generation that prevents, controls infectious disease, popular; Be used for the premunitive vaccine preventive biological products of human body; It is the generation of control disease effectively, uses the back not pollute, and does not have any residual; Can preserve the ecological environment effectively quality with consumable products, and life-time service can not produce drug resistance yet.Vaccine mainly comprises new generation vaccines such as inactivated vaccine and subunit vaccine, recombinant vaccine; Wherein the inactivated vaccine antibacterial that refers to select for use immunogenicity good, virus, rickettsia, spiral shell time body etc.; Through artificial culture, reuse physics or chemical method are killed it and are processed.This kind vaccine loses fertility, but keeps immunogenicity.Killed vaccine gets into behind the human body can not growth and breeding, short to the body stimulation time, obtain long-lasting immunity and need repeatedly repeated inoculation.With respect to new generation vaccines such as subunit vaccine, recombinant vaccines, inactivated vaccine advantage such as is convenient to make, simple with it and is had the advantage that can not be substituted.To Trionyx sinensis Wiegmann systematicness septicemia disease, all there is not the relevant research of method that prevents and treats at present both at home and abroad, more there is not correlational study report about Trionyx sinensis Wiegmann systematicness septicemia spherical viruses inactivated vaccine and preparation method thereof.
Summary of the invention
Technical problem to be solved by this invention provides a kind of inventor of utilization and in the Trionyx sinensis Wiegmann body of suffering from systemic septicemia, separates the systemic septicemia spherical viruses of the Trionyx sinensis Wiegmann that obtains as the Strain of producing vaccine; Prepare safety, the systemic septicemia spherical viruses inactivated vaccine of Trionyx sinensis Wiegmann effective, that immunity is strong and its preparation method is provided, simple, the easy row of the method for preparing of this inactivated vaccine.
The present invention solves the problems of the technologies described above the technical scheme that is adopted:
1, virus characteristic
Trionyx sinensis Wiegmann systematicness septicemia spherical viruses (Soft-shelled turtle systemic septicemia sphericalvirus; STSSSV); Strain is the p1015 strain; Preserving number was CGMCC No.5378, was deposited in China Committee for Culture Collection of Microorganisms common micro-organisms center on October 21st, 2011.This virus does not have cyst membrane, diameter 23-40nm, and nucleus is inside and outside all can breed.
2, a kind of Trionyx sinensis Wiegmann systematicness septicemia spherical viruses inactivated vaccine, this vaccine contain the Trionyx sinensis Wiegmann systematicness septicemia spherical viruses through deactivation that preserving number is CGMCC No.5378.
3, a kind of method for preparing of Trionyx sinensis Wiegmann systematicness septicemia spherical viruses inactivated vaccine, step is following:
(1) viral purification
Get the Trionyx sinensis Wiegmann that suffers from systemic septicemia, the Trionyx sinensis Wiegmann viscera tissue of will falling ill shreds, and in mass volume ratio 1g:10ml ratio the Trionyx sinensis Wiegmann internal organs is joined in the TNE buffer, under 4 ℃, behind the centrifugal 20min of 8000r/min, gets supernatant under 4 ℃, the centrifugal 1h of 35000g; Get core position, bottom white precipitate then, be resuspended in the 5mlTNE buffer, 4 ℃ of refrigerator ice baths spend the night; The deposition that to spend the night is blown and beaten evenly gently, under 4 ℃, and the centrifugal 20min of 8000r/min; Get supernatant under 4 ℃, the centrifugal 1h of 35000g, the white precipitate that obtains is purified virus;
(2) antigen deactivation
The purified virus that step (1) is obtained is diluted to virus protein final concentration 0.5-1mg/ml with 0.9% physiological saline solution; The formalin that adds final volume 0.5% then is in 37 ℃ of thermostat water bath deactivation 24h; Every 2-3h mixing that vibrates obtains aseptic inactivation of viruses;
(3) emulsifying
The inactivation of viruses that step (2) is obtained obtains Trionyx sinensis Wiegmann systematicness septicemia spherical viruses inactivated vaccine in 4 ℃ of intermittent oscillation emulsifying 6-8h after 1:1 mixes by volume with formula Freund's complete adjuvant not.
Described TNE buffer compound method: Tris 3.0289g, NaCl 6.00g, EDTA 0.9306g supply distilled water to 500ml, adjustment pH 7.6, and autoclaving, 4 ℃ of cold preservations are subsequent use.
Compared with prior art, the invention has the advantages that: a kind of Trionyx sinensis Wiegmann systematicness of the present invention septicemia spherical viruses inactivated vaccine and preparation method thereof has following advantage:
(1) the present invention has proposed Trionyx sinensis Wiegmann systematicness septicemia spherical viruses inactivated vaccine and preparation method thereof first, and the present invention is unique, production technology efficiently, and itself has primacy.
(2) it is less demanding to working condition to produce Trionyx sinensis Wiegmann systematicness septicemia spherical viruses inactivated vaccine by the present invention, is convenient to operation and enforcement, and the preparation process is simple, easy to be realized.
(3) under the natural conditions, virus mainly through Trionyx sinensis Wiegmann eat the disease Trionyx sinensis Wiegmann be with malicious Chi Shuijinpao to infect, (ID is by body weight＜100g, injection 0.1ml not reach the viral dosage injected in the efficacy test of the present invention; 100g＜body weight＜200g, injection 0.2ml; 200g＜body weight＜300g, injection 0.3ml; Body weight＞300g, injection 0.4ml), so the protective rate in the natural environment maybe be higher.
In sum, a kind of Trionyx sinensis Wiegmann of the present invention systematicness septicemia spherical viruses inactivated vaccine have safety, effectively, immunity is strong, the method for preparing of this inactivated vaccine is simple, be prone to row.
Trionyx sinensis Wiegmann systematicness septicemia spherical viruses (Soft-shelled turtle systemic septicemia sphericalvirus; STSSSV); Strain was the P1015 strain, and preserving number is CGMCC No.5378, was deposited in China Committee for Culture Collection of Microorganisms common micro-organisms center on October 21st, 2011; The preservation address is No. 3, Yard 1, BeiChen xi Road, Chaoyang District, Beijing City, Institute of Microorganism, Academia Sinica.
Description of drawings
Fig. 1 is the electron microscopic observation result of the Trionyx sinensis Wiegmann systematicness septicemia spherical viruses particle of purification.
The specific embodiment
Embodiment describes in further detail the present invention below in conjunction with accompanying drawing.
One, specific embodiment
A kind of Trionyx sinensis Wiegmann systematicness of the present invention septicemia spherical viruses inactivated vaccine, this vaccine contain the Trionyx sinensis Wiegmann systematicness septicemia spherical viruses through deactivation that preserving number is CGMCC No.5378.This Trionyx sinensis Wiegmann systematicness septicemia spherical viruses (Soft-shelled turtle systemic septicemia spherical virus; STSSSV); Strain is the P1015 strain; Preserving number was CGMCC No.5378, was deposited in China Committee for Culture Collection of Microorganisms common micro-organisms center on October 21st, 2011.This virus does not have cyst membrane, diameter 23-40nm, and nucleus is inside and outside all can breed.Concrete method for preparing is following:
(1) viral purification
Get the Trionyx sinensis Wiegmann that suffers from systemic septicemia, the Trionyx sinensis Wiegmann viscera tissue of will falling ill shreds, and in mass volume ratio 1g: the 10ml ratio joins the Trionyx sinensis Wiegmann internal organs in the TNE buffer, under 4 ℃, behind the centrifugal 20min of 8000r/min, gets supernatant under 4 ℃, the centrifugal 1h of 35000g; Get core position, bottom white precipitate then, be resuspended in the 5mlTNE buffer, 4 ℃ of refrigerator ice baths spend the night; The deposition that to spend the night is blown and beaten evenly gently, under 4 ℃, and the centrifugal 20min of 8000r/min; Get supernatant under 4 ℃, the centrifugal 1h of 35000g, the white precipitate that obtains is purified virus;
(2) antigen deactivation
The purified virus that step (1) is obtained is diluted to virus protein final concentration 0.5mg/ml with 0.9% physiological saline solution; The formalin that adds final volume 0.5% then is in 37 ℃ of thermostat water bath deactivation 24h, and every 2-3h mixing that vibrates obtains aseptic inactivation of viruses;
(3) emulsifying
Inactivation of viruses with after not the formula Freund's complete adjuvant mixed in 1: 1 by volume, is obtained Trionyx sinensis Wiegmann systematicness septicemia spherical viruses inactivated vaccine in 4 ℃ of intermittent oscillation emulsifying 6h.
TNE buffer compound method: Tris 3.0289g, NaCl 6.00g, EDTA 0.9306g supply distilled water to 500ml, adjustment pH 7.6, and autoclaving, 4 ℃ of cold preservations are subsequent use.
Except that the foregoing description, the virus protein final concentration can also be 1mg/ml or 0.75mg/ml; The vibration emulsification times of having a rest can also be 7h or 8h.
Two, the method for inspection
1, product inspection: adequately emulsified inactivated vaccine is the milky oil emulsion, get one after another drop ofly not scatter in 5min waterborne, 4 ℃ place 15 days not stratified.
2, aseptic detection: get 100ul Trionyx sinensis Wiegmann systematicness septicemia spherical viruses inactivated vaccine, coating beef agar plate is inverted for 28 ℃ and is cultivated 24-48h, observes to have or not bacterial growth.Asepsis growth is qualified.
3, safety detection:
A. get the inactivated vaccine inoculated into chick embryo, every embryo 0.15ml cultivated 10 days for 34 ℃, observed the chicken embryo death situation;
B. get inactivated vaccine inoculation Trionyx sinensis Wiegmann, every 0.3ml observes death condition in the Trionyx sinensis Wiegmann 10 days;
It is qualified not having death in egg inoculation 3-10d and the Trionyx sinensis Wiegmann inoculation 15d.
4, efficacy test
(1) immunity
The different size Trionyx sinensis Wiegmann is by back leg intramuscular injection vaccine, and other establishes matched group by body weight injection corresponding dosage normal saline.
Immunity is carried out to Trionyx sinensis Wiegmann in fully emulsified back, and ID is by body weight < 100g, injection 0.1ml; 100g <body weight < 200g, injection 0.2ml; 200g <body weight < 300g, injection 0.3ml; Body weight>300g, injection 0.4ml.Other establishes matched group, by body weight injection corresponding dosage normal saline.
(2) slightly improve concentration virus liquid as counteracting toxic substances liquid by Trionyx sinensis Wiegmann incidence tissue
A. get the Trionyx sinensis Wiegmann that suffers from systemic septicemia typical case disease symptom and dissect, get internal organs and put into the beaker that is embedded in the ice;
B. viscera tissue is shredded by the homogenate of m/v=1g:10ml adding TM buffer, in 4 ℃, under the 6000g condition, centrifugal 20min gets supernatant;
C. centrifugal gained deposition is resuspended with a small amount of TM buffer, homogenate once more, in 4 ℃, the centrifugal 20min of 6000g merges two times centrifugal gained supernatant;
After the membrane filtration that d. will merge gained supernatant via hole diameter 0.45 μ m is removed broken tissue, will filtrate again, by volume every milliliter of filtrating adding 1000IU penicillin and 1000 μ g streptomycins through 0.22 μ m pin type filter filtration sterilization;
E. putting into 4 ℃ of refrigerator ice baths spends the night and promptly gets counteracting toxic substances liquid.
The Trionyx sinensis Wiegmann of (3) getting immune 15 days carries out the counteracting toxic substances experiment, and the experimental group injection is through the counteracting toxic substances liquid of method for preparing, and the same immunizing dose of dosage, is observed death condition in 3-10 day by 50 every group.
Mortality rate is 100% behind the matched group counteracting toxic substances of injecting normal saline as a result; Injection inactivated vaccine group all is lower than 50% with mortality rate behind the counteracting toxic substances liquid injection counteracting toxic substances, and the result shows that vaccine has obvious protection to render a service to Trionyx sinensis Wiegmann.
Satisfy above four kinds of examination requirementses be regarded as qualified.
Claims (3)
1. Trionyx sinensis Wiegmann systematicness septicemia spherical viruses inactivated vaccine, it is characterized in that: this vaccine contains the Trionyx sinensis Wiegmann systematicness septicemia spherical viruses through deactivation that preserving number is CGMCC No.5378.
2. the method for preparing of a Trionyx sinensis Wiegmann according to claim 1 systematicness septicemia spherical viruses inactivated vaccine is characterized in that step is following:
(1) viral purification
Get the Trionyx sinensis Wiegmann that suffers from systemic septicemia, the Trionyx sinensis Wiegmann viscera tissue of will falling ill shreds, and in mass volume ratio 1g:10ml ratio the Trionyx sinensis Wiegmann internal organs is joined in the TNE buffer, under 4 ℃, behind the centrifugal 20min of 8000r/min, gets supernatant under 4 ℃, the centrifugal 1h of 35000g; Get core position, bottom white precipitate then, be resuspended in the 5mlTNE buffer, 4 ℃ of refrigerator ice baths spend the night; The deposition that to spend the night is blown and beaten evenly gently, under 4 ℃, and the centrifugal 20min of 8000r/min; Get supernatant under 4 ℃, the centrifugal 1h of 35000g, the white precipitate that obtains is purified virus;
(2) antigen deactivation
The purified virus that step (1) is obtained is diluted to virus protein final concentration 0.5-1mg/ml with 0.9% physiological saline solution; The formalin that adds final volume 0.5% then is in 37 ℃ of thermostat water bath deactivation 24h; Every 2-3h mixing that vibrates obtains aseptic inactivation of viruses;
(3) emulsifying
The inactivation of viruses that step (2) is obtained obtains Trionyx sinensis Wiegmann systematicness septicemia spherical viruses inactivated vaccine in 4 ℃ of intermittent oscillation emulsifying 6-8h after 1:1 mixes by volume with formula Freund's complete adjuvant not.
3. the method for preparing of a kind of Trionyx sinensis Wiegmann systematicness septicemia spherical viruses inactivated vaccine according to claim 2; It is characterized in that: described TNE buffer compound method: Tris 3.0289g, NaCl 6.00g, EDTA 0.9306g supply distilled water to 500ml; Adjustment pH 7.6; Autoclaving, 4 ℃ of cold preservations are subsequent use.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210018723 CN102626514B (en) | 2012-01-20 | 2012-01-20 | Soft-shelled turtle systemic septicemia spherical virus inactivated vaccine and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210018723 CN102626514B (en) | 2012-01-20 | 2012-01-20 | Soft-shelled turtle systemic septicemia spherical virus inactivated vaccine and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102626514A true CN102626514A (en) | 2012-08-08 |
| CN102626514B CN102626514B (en) | 2013-10-02 |
Family
ID=46585021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210018723 Expired - Fee Related CN102626514B (en) | 2012-01-20 | 2012-01-20 | Soft-shelled turtle systemic septicemia spherical virus inactivated vaccine and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102626514B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103013932A (en) * | 2012-12-26 | 2013-04-03 | 宁波大学 | Quick purifying method of portunus trituberculatus reovirus |
| CN104459119A (en) * | 2014-11-14 | 2015-03-25 | 宁波大学 | Soft-shelled turtle systemic septicemia virus detection test strip and preparation method thereof |
| CN106377502A (en) * | 2016-10-12 | 2017-02-08 | 中崇信诺生物科技泰州有限公司 | Emulsifying method for animal inactivated vaccine |
| CN109096389A (en) * | 2017-06-21 | 2018-12-28 | 宁波大学 | A kind of soft-shelled turtle systemic septicaemia spherical viruses STSSSV blocking agent and its preparation method and application |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1188673A (en) * | 1997-01-22 | 1998-07-29 | 王卯光 | Soft-shelled turtle tetra vaccinum and preparation method |
| CN101926994A (en) * | 2010-08-19 | 2010-12-29 | 中国医学科学院医学生物学研究所 | Turtle shell immunoadjuvant and influenza vaccine containing the same |
-
2012
- 2012-01-20 CN CN 201210018723 patent/CN102626514B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1188673A (en) * | 1997-01-22 | 1998-07-29 | 王卯光 | Soft-shelled turtle tetra vaccinum and preparation method |
| CN101926994A (en) * | 2010-08-19 | 2010-12-29 | 中国医学科学院医学生物学研究所 | Turtle shell immunoadjuvant and influenza vaccine containing the same |
Non-Patent Citations (2)
| Title |
|---|
| 叶永青: "土法疫苗预防甲鱼疖疮病的试验", 《科学养鱼》 * |
| 郝贵杰等: "中华鳖细菌疫苗免疫佐剂的筛选及其初步应用", 《大连水产学院学报》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103013932A (en) * | 2012-12-26 | 2013-04-03 | 宁波大学 | Quick purifying method of portunus trituberculatus reovirus |
| CN104459119A (en) * | 2014-11-14 | 2015-03-25 | 宁波大学 | Soft-shelled turtle systemic septicemia virus detection test strip and preparation method thereof |
| CN104459119B (en) * | 2014-11-14 | 2016-04-13 | 宁波大学 | A kind of soft-shelled turtle systemic septicaemia Viral diagnosis test strips and preparation method thereof |
| CN106377502A (en) * | 2016-10-12 | 2017-02-08 | 中崇信诺生物科技泰州有限公司 | Emulsifying method for animal inactivated vaccine |
| CN109096389A (en) * | 2017-06-21 | 2018-12-28 | 宁波大学 | A kind of soft-shelled turtle systemic septicaemia spherical viruses STSSSV blocking agent and its preparation method and application |
| CN109096389B (en) * | 2017-06-21 | 2022-09-23 | 宁波大学 | Soft-shelled turtle systemic sepsis spherical virus STSSV blocking agent and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102626514B (en) | 2013-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103263666B (en) | Porcine circovirus 2 type, porcine mycoplasmal pneumonia bivalent inactivated vaccine and preparation method thereof | |
| CN102086447B (en) | Duck virus hepatitis strains and inactivated vaccine | |
| CN102626514B (en) | Soft-shelled turtle systemic septicemia spherical virus inactivated vaccine and its preparation method | |
| CN102492661B (en) | Preparation method and application of immunization preparation for controlling novel duck reovirus | |
| CN104892756A (en) | Antibacterial chicken egg yolk complex antibody as well as preparation method and application thereof | |
| CN103820397B (en) | A kind of kind Duck parvovirus and application thereof | |
| CN103305474A (en) | Porcine pseudorabies virus strain as well as inactivated vaccine and applications thereof | |
| CN105949307B (en) | It is a kind of for preventing and treating a kind Yolk antibody for duck source gosling plague | |
| CN103833848B (en) | A kind of Yolk antibody for prophylactic treatment kind Duck parvovirus disease | |
| CN105031638A (en) | Trivalent inactivated vaccine against Newcastle disease, avian influenza and infectious bursal disease | |
| CN101575592A (en) | Virulent phage sensitive to riemerella anatipestifer and application thereof | |
| CN104087559B (en) | A kind of infectious bursa of Fabricius virus, inactivated vaccine and preparation method thereof | |
| CN102755644B (en) | Rabbit haemorrhagic disease tissue inactivated vaccine and preparation method thereof | |
| CN105087501B (en) | Porcine circovirus type 2 strain and inactivated vaccine prepared therefrom and application | |
| CN103830724B (en) | Muscovy duck parvovirus inactivation vaccine and application thereof | |
| CN101269218A (en) | Fortifier, special bait, injection for bleeding disease immunity of Chinese idle and novel immunity method | |
| CN102952785B (en) | Porcine pseudorabies virus, and vaccine composition and applications thereof | |
| CN104069489B (en) | Newcastle disease and infectious bursa of Fabricius bivalent inactivated vaccine and preparation method thereof | |
| CN106310247B (en) | The preparation method of gosling plague inactivated vaccine and its inactivated vaccine of preparation | |
| CN105920596A (en) | Muscovy duck parvovirus and gosling plague bivalent vaccine | |
| CN103122336A (en) | Goose parvovirus H-strain and application thereof in preventing and treating gosling plague | |
| CN102276720A (en) | High-biological-activity egg yolk antibody and preparation method thereof | |
| CN102757494B (en) | Preparation method of chicken egg yolk antibody against duck flavivirus | |
| CN108588034A (en) | A kind of rabbit hemorrhagic disease virus of variation and its application in preparing inactivated vaccine | |
| CN104388396A (en) | Porcine pseudorabies virus strain, inactivated vaccine prepared from porcine pseudorabies virus strain and application of porcine pseudorabies virus strain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131002 Termination date: 20190120 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |